semaglutide weight loss treatment henderson Your journey shouldn't be a solo mission. At our clinic, every Weight Loss Therapy | Mobile

If you have specific questions about your dosage or dosage amount, we encourage you to reach out directly via the Alan Health portal

2025 Wegovy Study Shows Increase in NAION Risk for Diabetes Patients A 2025 study in JAMA Ophthalmology investigated the risk of NAION in people with Type 2 diabetes using semaglutide (Wegovy)

Semaglutide is a compounded GLP-1 medication and the active ingredient in Rybelsus, Ozempic and Wegovy

It is strongly linked to increased risk of cardiovascular disease, type 2 diabetes, and metabolic syndrome

While different questions used different semantics, the drops were consistent: from 53 percent to 15 percent for those who had uncontrollable food thoughts, from 60 percent to 20 percent for those whose food thoughts had negative effects, and from 47 percent to 15 percent for those whose food thoughts distracted them from everyday life

However, tirzepatide was removed from the FDA drug shortage list, triggering restrictions on compounded versions